Financials Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Delayed Hong Kong S.E. 09:13:54 02/07/2024 am IST 5-day change 1st Jan Change
3.26 HKD +0.31% Intraday chart for Abbisko Cayman Limited -3.55% -10.68%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 5,209 1,990 2,149 1,960 - -
Enterprise Value (EV) 1 2,718 -223.7 177.8 31.3 574.1 1,257
P/E ratio -0.96 x -3.54 x -4.95 x -3.69 x -3.22 x -3.12 x
Yield - - - - - -
Capitalization / Revenue 230 x - 113 x 7.78 x 7.03 x 7.18 x
EV / Revenue 120 x - 9.33 x 0.12 x 2.06 x 4.61 x
EV / EBITDA -8.6 x 0.46 x -0.36 x -0.65 x -0.94 x -1.82 x
EV / FCF -15.2 x 0.62 x -0.39 x -0.18 x -47.8 x -3.89 x
FCF Yield -6.58% 162% -256% -562% -2.09% -25.7%
Price to Book 2.05 x 0.75 x 1.08 x 1.09 x 1.72 x 3.29 x
Nbr of stocks (in thousands) 7,02,578 7,01,774 6,47,858 6,47,858 - -
Reference price 2 7.415 2.835 3.318 3.025 3.025 3.025
Announcement Date 18/03/22 15/03/23 12/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 22.68 - 19.06 252 278.6 272.8
EBITDA 1 -316.2 -481.4 -492.7 -48.14 -608.6 -689.5
EBIT 1 -328.2 -497.2 -511.1 -54.67 -227.3 -543.2
Operating Margin -1,447.05% - -2,681.41% -21.69% -81.56% -199.16%
Earnings before Tax (EBT) 1 -1,810 -495.6 -431.6 -50 - -
Net income 1 -1,810 -495.6 -431.6 -696.4 -914.6 -1,038
Net margin -7,979.87% - -2,264.34% -276.35% -328.23% -380.55%
EPS 2 -7.710 -0.8000 -0.6700 -0.8200 -0.9400 -0.9700
Free Cash Flow 1 -178.8 -363.5 -454.3 -176 -12 -323
FCF margin -788.09% - -2,383.68% -69.84% -4.31% -118.42%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - - - - -
Announcement Date 18/03/22 15/03/23 12/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 - - - 19.06 - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Operating Margin - - - - - - -
Earnings before Tax (EBT) - - - - - - -
Net income - - - - -223 -306.4 -390
Net margin - - - - - - -
EPS - - - - -0.3500 -0.3700 -0.4500
Dividend per Share - - - - - - -
Announcement Date 22/08/22 22/08/22 15/03/23 15/08/23 12/03/24 - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 2,492 2,213 1,971 1,928 1,385 702
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -179 -364 -454 -176 -12 -323
ROE (net income / shareholders' equity) -253% -20.3% -19.9% -1.9% -34.7% -62.7%
ROA (Net income/ Total Assets) -109% -20.6% -19.4% -2.3% - -
Assets 1 1,660 2,402 2,225 30,278 - -
Book Value Per Share 2 3.610 3.780 3.060 2.770 1.760 0.9200
Cash Flow per Share 2 -0.7200 -0.5500 -0.6900 -0.2400 - -
Capex 1 9.01 19.6 12.3 25 25 25
Capex / Sales 39.74% - 64.28% 9.92% 8.97% 9.17%
Announcement Date 18/03/22 15/03/23 12/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.025 CNY
Average target price
8.078 CNY
Spread / Average Target
+167.06%
Consensus
  1. Stock Market
  2. Equities
  3. 2256 Stock
  4. Financials Abbisko Cayman Limited